News

In addition, Mr Grossman will also be assuming the role of co-CEO, with no remuneration, to assist in XTL’s analysis of its strategic alternatives. Mr Grossman served as

The clinical study will assess the performance of OralAdvance compared to the gold standard biopsy and histology for its ability to differentiate between visually suspicious oral lesions with

Jeffrey Buchalter, chairman and CEO of Enzon, said: “As we previously demonstrated, Enzon maintains high standards for developing its important and novel compounds. While it did not achieve

Mr Blanchard brings more than 20 years of leadership experience in the global life sciences market to his new role, including senior level positions in corporate development, operations

Taro’s levetiracetam oral solution is a prescription medication used as an adjunctive therapy in the treatment of partial onset seizures in individuals with epilepsy. This new Taro product

Singapore-based Invida Pharmaceutical Holdings will market Sancuso in Australia, Indonesia, the Philippines, Thailand and Vietnam, while Dubai-based NewBridge Pharmaceuticals will market Sancuso in Turkey. ProStrakan has already partnered

Widely published in scientific journals and with over 100 invited presentations, Caniggia also serves as a reviewer for a number of leading peer-reviewed scientific journals and has been

The offer replaces the previous proposal made by Roche in July 2008 to acquire all of the publicly held shares of Genentech at a price of $89 per

Revenues for the second quarter decreased $404,012 or 16.8% vs. the prior year’s comparable quarter; of this, $179,365 was a reduction in contract manufacturing revenue primarily due to